UBS Group’s Panbela Therapeutics, Inc. Common Stock PBLA Stock Holding History

UBS Group’s Portfolio PBLA Stock Details PBLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-41	Closed	-$1.89K	–	10382
2023 Q2	$1.89K	Sell	41 -14	-25%	-$2.84K	﹤0.01%	7840
2023 Q1	$14.5K	Buy	55 +46	+511%	+$44.6K	﹤0.01%	7344
2022 Q4	$14.9K	Buy	9 +1	+13%	+$3.41K	﹤0.01%	8027
2022 Q3	$51K	Buy	+8	New	+$168K	﹤0.01%	6346
2022 Q2	–	Hold	0	–	–	–	11646
2022 Q1	–	Hold	0	–	–	–	9591
2021 Q4	–	Hold	0	–	–	–	9478
2021 Q3	–	Hold	0	–	–	–	9098
2021 Q2	–	Hold	0	–	–	–	9301

Other funds holding PBLA

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

UBS Group's PBLA Position: Q3 2023 in Review

UBS Group sold out of Panbela Therapeutics, Inc. Common Stock (PBLA) in Q3 2023, closing a stake of 41 shares — an estimated $1.89K sold.

UBS Group first reported a position in PBLA in Q3 2022 and held it in 4 quarters. The position peaked at $51K in Q3 2022. 5 funds tracked by Wall St. Rank hold PBLA as of Q3 2023.

UBS Group reported no remaining Panbela Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
UBS Group sold 41 Panbela Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $1.89K.
UBS Group first reported a position in Panbela Therapeutics, Inc. Common Stock in Q3 2022 and held it in 4 quarters.
UBS Group's Panbela Therapeutics, Inc. Common Stock position peaked at $51K in Q3 2022.
5 funds tracked by Wall St. Rank held Panbela Therapeutics, Inc. Common Stock as of Q3 2023.

Based on UBS Group's 13F filing for Q3 2023, filed 9 Nov 2023.